Mayzent

Chemical Namesiponimod
Dosage FormTablet (oral; 0.25 mg, 2 mg)
Drug ClassModulators
SystemNervous
CompanyNovartis
Approval Year2019

Indication

  • Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Last updated on 2/5/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Mayzent (siponimod) Prescribing Information2019Novartis